Trials / Completed
CompletedNCT01310413
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 842 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Accepted
Summary
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to \< 18 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Influenza A (H5N1) Virus monovalent vaccine | All subjects will receive 2 doses administered as an intramuscular (IM) injection. |
| BIOLOGICAL | Saline placebo | All subjects will receive 2 doses administered as an intramuscular (IM) injection. |
Timeline
- Start date
- 2011-03-07
- Primary completion
- 2011-07-21
- Completion
- 2014-01-26
- First posted
- 2011-03-08
- Last updated
- 2021-11-01
- Results posted
- 2014-03-31
Locations
17 sites across 3 countries: United States, Canada, Thailand
Source: ClinicalTrials.gov record NCT01310413. Inclusion in this directory is not an endorsement.